An APRIL to remember: Novel TNF ligands as therapeutic targets

Nature Reviews Drug Discovery

Volumn 5, Issue 3, 2006, Pages 235-246

  Dillon, Stacey R ^a   Gross, Jane A ^a   Ansell, Stephen M ^b   Novak, Anne J ^b  

^a ZYMOGENETICS INC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 623; ANTIINFLAMMATORY AGENT; APRIL PROTEIN; BELIMUMAB; DEXAMETHASONE; IMMUNOGLOBULIN; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; DRUG DESIGN; HUMANS; LIGANDS; MEMBRANE PROTEINS; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644755600     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1982     Document Type: Review

References (104)

1. Bodmer, J. L., Schneider, P. & Tschopp, J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27, 19-26 (2002).
2. Hahne, M. et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med. 188, 1185-1190 (1998).
3. Shu, H. B., Hu, W. H. & Johnson, H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukoc. Biol. 65, 680-683 (1999).
4. Kelly, K., Manos, E., Jensen, G., Nadauld, L. & Jones,D. A. APRIL/ TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res. 60, 1021-1027 (2000).
5. Moore, P. A. et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260-263 (1999).
6. Schneider, P. et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189, 1747-1756 (1999).
7. Mukhopadhyay, A., Ni, J., Zhai, Y., Yu, G. L. & Aggarwal, B. B. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J. Biol. Chem. 274, 15978-15981 (1999).
8. Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995-999 (2000).
9. von Bulow, G. U. & Bram, R. J. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278, 138-141 (1997).
10. Gras, M. P. et al. BCMAp: An integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int. Immunol. 7, 1093-1106 (1995).
11. Thompson, J. S. et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293, 2108-2111 (2001).
12. Yan, M. et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11, 1547-1552 (2001).
13. Lentz, V. M., Hayes, C. E. & Cancro, M. P. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J. Immunol. 160, 3743-3747 (1998).
14. Ingold, K. et al. Identification of proteoglycans as the APRIL-specific binding partners. J. Exp. Med. 201, 1375-1383 (2005).
15. Hendriks, J. et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 12, 637-648 (2005).
16. Roschke, V. et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J. Immunol. 169, 4314-4321 (2002).
17. Kalled, S. L., Ambrose, C. & Hsu, Y. M. The biochemistry and biology of BAFF, APRIL and their receptors. Curr. Dir. Autoimmun. 8, 206-242 (2005).
18. Mackay, F., Sierro, F., Grey, S. T. & Gordon, T. P. The BAFF/APRIL system: An important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8, 243-265 (2005).
19. Kalled, S. L. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev. 204, 43-54 (2005).
20. Ng, L. G., Mackay, C. R. & Mackay, F. The BAFF/APRIL system: Life beyond B lymphocytes. Mol. Immunol. 42, 763-772 (2005).
21. Schneider, P. The role of APRIL and BAFF in lymphocyte activation. Curr. Opin. Immunol. 17, 282-289 (2005).
22. Zola, H. et al. CD molecules 2005: Human cell differentiation molecules. Blood (2005).
23. Pradet-Balade, B. et al. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J. 21, 5711-5720 (2002).
24. Wallweber, H. J., Compaan, D. M., Starovasnik, M. A. & Hymowitz, S. G. The crystal structure of a proliferation-inducing ligand, APRIL. J. Mol. Biol. 343, 283-290 (2004).
25. Lopez-Fraga, M., Fernandez, R., Albar, J. P. & Hahne, M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2, 945-951 (2001).
26. Nardelli, B. et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97, 198-204 (2001).
27. Kolfschoten, G. M., Pradet-Balade, B., Hahne, M. & Medema, J. P. TWE-PRIL; a fusion protein of TWEAK and APRIL. Biochem. Pharmacol. 66, 1427-1432 (2003).
28. Yan, M. et al. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nature Immunol. 1, 37-41 (2000).
29. Marsters, S. A. et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr. Biol. 10, 785-788 (2000).
30. Wu, Y. et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J. Biol. Chem. 275, 35478-35485 (2000).
31. Yu, G. et al. APRIL and TALL-I and receptors BCMA and TACI: System for regulating humoral immunity. Nature Immunol. 1, 252-256 (2000).
32. Liu, Y. et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 423, 49-56 (2003).
33. Hymowitz, S. G. et al. Structures of APRIL-receptor complexes: Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem. 280, 7218-7227 (2005).
34. Gordon, N. C. et al. BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry 42, 5977-5983 (2003).
35. Kim, H. M. et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nature Struct. Biol. 10, 342-348 (2003).
36. Patel, D. R. et al. Engineering an APRIL-specific B cell maturation antigen. J. Biol. Chem. 279, 16727-16735 (2004).
37. Mackay, F. & Ambrose, C. The TNF family members BAFF and APRIL: The growing complexity. Cytokine Growth Factor Rev. 14, 311-324 (2003).
38. Rennert, P. et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192, 1677-1184 (2000).
39. Schneider, P. et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205-1213 (1998).
40. Holler, N. et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell Biol. 23, 1428-1440 (2003).
41. Bishop, G. A. & Hostager, B. S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev. 14, 297-309 (2003).
42. Couchman, J. R. Syndecans: Proteoglycan regulators of cell-surface microdomains? Nature Rev. Mol. Cell Biol. 4, 926-937 (2003).
43. Day, E. S. et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44, 1919-1931 (2005).
44. Litinskiy, M. B. et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunol. 5, 822-829 (2002).
45. Craxton, A., Magaletti, D., Ryan, E. J. & Clark, E. A. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101, 4464-4471 (2003).
46. Moreaux, J. et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106, 1021-1030 (2005).
47. Ohata, J. et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J. Immunol. 174, 864-870 (2005).
48. Deshayes, F. et al. Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene 23, 3005-3012 (2004).
49. Novak, A. J., Bram, R. J., Kay, N. E. & Jelinek, D. F. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: A mechanism for survival. Blood 100, 2973-2979 (2002).
50. Kern, C. et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103, 679-688 (2004).
51. Novak, A. J. et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood 104, 2247-2253 (2004).
52. Novak, A. J. et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood 103, 689-694 (2004).
53. He, B. et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J. Immunol. 172, 3268-3279 (2004).
54. Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148-3157 (2004).
55. Nishio, M. et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood 106, 1012-1020 (2005).
56. Viau, M. & Zouali, M. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114, 17-26 (2005).
57. Ng, L. G. et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 173, 807-817 (2004).
58. Laabi, Y. et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 22, 1147-1154 (1994).
59. Seyler, T. M. et al. BLyS and APRIL in rheumatoid arthritis. J. Clin. Invest. 115, 3083-3092 (2005).
60. Ye, Q. et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur. J. Immunol. 34, 2750-2759 (2004).
61. Stein, J. V. et al. APRIL modulates B and T cell immunity. J. Clin. Invest. 109, 1587-1598 (2002).
62. Castigli, E. et al. Impaired IgA class switching in APRIL-deficient mice. Proc. Natl Acad. Sci. USA 101, 3903-3908 (2004).
63. Avery, D. T. et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112, 286-297 (2003).
64. O'Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91-98 (2004).
65. Yang, M. et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J. Immunol. 175, 2814-2824 (2005).
66. Hatzoglou, A. et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-κB, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J. Immunol. 165, 1322-1330 (2000).
67. Bonci, D., Hahne, M., Felli, N., Peschle, C. & De Maria,R. Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis. Blood 104, 3169-3172 (2004).
68. Varfolomeev, E. et al. APRIL-deficient mice have normal immune system development. Mol. Cell Biol. 24, 997-1006 (2004).
69. Planelles, L. et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6, 399-408 (2004).
70. Gross, J. A. et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS. Immunity 15, 289-302 (2001).
71. Schneider, P. et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J. Exp. Med. 194, 1691-1697 (2001).
72. von Bulow, G. U., van Deursen, J. M. & Bram, R. J. Regulation of the T-independent humoral response by TACI. Immunity 14, 573-582 (2001).
73. Yan, M. et al. Activation and accumulation of B cells in TACI-deficient mice. Nature Immunol. 2, 638-643 (2001).
74. Seshasayee, D. et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18, 279-288 (2003).
75. Xu, S. & Lam, K. P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. 21, 4067-4074 (2001).
76. Schiemann, B. et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111-2114 (2001).
77. Shulga-Morskaya, S. et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 173, 2331-2341 (2004).
78. Landers, C. D., Chelvarajan, R. L. & Bondada, S. The role of B cells and accessory cells in the neonatal response to Tl-2 antigens. Immunol Res. 31, 25-36 (2005).
79. Castigli, E. et al. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201, 35-39 (2005).
80. Jabara, H. et al. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching. Immunity 17, 265-276 (2002).
81. Koyama, T. et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64, 1065-1067 (2005).
82. Stohl, W. et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 63, 1096-1103 (2004).
83. Koyama, T. et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (Oxford) 42, 980-985 (2003).
84. Ramanujam, M. et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 173, 3524-3534 (2004).
85. Odendahl, M. et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970-5979 (2000).
86. Tan, S. M. et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 48, 982-992 (2003).
87. Cheema, G. S., Roschke, V., Hilbert, D. M. & Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313-1319 (2001).
88. Wang, H. et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nature Immunol. 2, 632-637 (2001).
89. Groom, J. et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109, 59-68 (2002).
90. Mariette, X. et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 62, 168-171 (2003).
91. Jonsson, M. V., Szodoray, P., Jellestad, S., Jonsson, R. & Skarstein, K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J. Clin. Immunol. 25, 189-201 (2005).
92. Uccelli, A., Aloisi, F. & Pistoia, V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 26, 254-259 (2005).
93. Thangarajh, M. et al. Increased levels of APRIL (A Proliferation-Inducing Ligand) mRNA in multiple sclerosis. J. Neuroimmunol. 167, 210-214 (2005).
94. Thangarajh, M., Gomes, A., Masterman, T., Hillert, J. & Hjelmstrom, P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J. Neuroimmunol. 152, 183-190 (2004).
95. Salzer, U. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nature Genet. 37, 820-828 (2005).
96. Castigli, E. et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nature Genet. 37, 829-834 (2005).
97. Roth, W. et al. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ. 8, 403-410 (2001).
98. Okano, H. et al. Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization. World J. Gastroenterol. 11, 4650-4654 (2005).
99. Craxton, A., Draves, K. E., Gruppi, A. & Clark, E. A. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J. Exp. Med. 202, 1363-1374 (2005).
100. Foger, N., Marhaba, R. & Zoller, M. Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J. Cell Sci. 114, 1169-1178 (2001).
101. Baker, K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253-3265 (2003).
102. Pelletier, M. et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J. Biol. Chem. 278, 33127-33133 (2003).
103. Ruben, S. M. Antibodies against tumor necrosis factor delta (APRIL). Patent. US 2003/0059862 A1 (2003).
104. Kelley, R. F. & Patel, D. Variants of the extracellular domain of BCMA and uses thereof. Patent. WO 2005/075511 A1 (2005).